Federal Register #E2632023

NIH Licensing Opportunity: Soluble Tissue Factor and Antibody Platform for Thrombosis Applications

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), offers a license for a novel Soluble Tissue Factor (sTF) and humanized monoclonal antibody platform for thrombosis-related applications. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - OEMs and Vendors: - National Cancer Institute (NCI) - National Institutes of Health (NIH) - Products/Services Requested: - Licensing and/or collaborative development of: - Soluble Tissue Factor (sTF) and humanized monoclonal antibodies (e.g., 58B3, 56E5) - Diagnostic kits (ELISA, point-of-care assays) - Radiolabeled antibody diagnostics - Therapeutic applications for thrombosis and related conditions - Unique/Notable Requirements: - Platform selectively neutralizes pathological coagulation while preserving normal hemostasis - Validated for use in cancer, sepsis, infectious diseases (including COVID), autoimmune disorders, trauma, heart conditions, and inflammatory diseases - Offers more sensitive and specific thrombosis testing than D-dimer - Applicable to necroptosis, pyroptosis, and NETtosis - Invention is at pre-clinical (in vivo validation) stage and available for further development and commercialization - NIH seeks partners for licensing and co-development

Description

Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic, and prognostic target for thrombosis called Soluble Tissue Factor (sTF). NCI has developed first-in-class antibodies and a platform technology that selectively neutralizes pathological coagulation while preserving normal hemostasis. This technology can be used to prevent, diagnose, and treat pathological thrombosis caused by various clinical conditions including cancer, sepsis, infectious diseases, autoimmune disorders, trauma, heart conditions, and inflammatory conditions. The invention offers a more sensitive and specific test for thrombosis than the current D-dimer test and may be applicable to a wide range of diseases involving inflammatory cell death pathways.

View original listing